Table 1 Predisposing or protective genetic factors in the development of severe COVID-19

ACE2 SNPs

rs2285666 (3’ fold)

TMPRSS2 SNPs

rs12329760 (OR: 0.89)

HLA system haplotype and alleles

Class HLA I: A*11:01 (OR:2.23); B*51:01 (OR: 3.38); C*04:01 (2’ fold); C*14:02 (OR 4.72)

Class HLA II: rs9271609 HLA-DRB1 (OR 1.1)

HLA I: A*02:01; A*03:01 (only in homozygosis); A*68:02 (OR 0.448); B*14 (OR: 0.434)

TLR3 mutation and SNPs

Autosomal dominant mutations present only in severe patients (p.Ser339fs/WT, p.Pro554Ser/WT, p.Trp769*/WT, p.Met870Val/WT);

rs3775291 (r = 0.33)

TLR7 mutation and SNPs

Recessive X-linked mutations present only in severe patients (L134P/Y, N158Tfs11*/Y, L227fs*/Y, D244Y/Y, F310L/Y, L372M, I505T/Y, H630Y/Y, I657T/Y, F670Lfs*8, F670Lfs*8, K684*/Y, P715S/Y, H781L/Y, L988S/Y, L988S/Y and M854I;L988S/Y)

IFNAR2 SNPs

rs2236757 (OR 1.2), rs13050728 (OR 1.3)

OAS-1, -3 SNPs

rs10735079 (OR 1.3)

IRF7

Autosomal recessive mutations (p.Pro364fs/p.Pro364f;p.Met371Val/p.Asp117Asn)

Autosomal dominant mutations

(p.Arg7fs/WT, p.Gln185*/WT, p.Pro246fs/WT, p.Arg369Gln/WT, p.Phe95Ser/WT)

IFNs

Serum auto-antibodies against IFN-I (IFNα,IFNω) and IFN-II;

rs28368148 of IFNA10 (OR 1.7)

Absence of serum auto-antibodies against IFNs I (IFNα, IFNω) and IFN II

IFITIM3

rs12252 (GA and GG genotype OR 2.2; C genotype OR 1.6)

IL-10RB

rs8178521 (OR 1.2)

CCR5

rs9845542 (OR 1.33), rs12639314 (OR 1.23) and rs35951367 (OR 1.32)

deletion of CCR5Δ32 rs333 (OR:0.66)

ABO blood group and SNPs related

A group; rs657152 (OR 1.7), rs 9,411,378 (OR 1.2); FUT2 rs 48,697,960 (CT genotype OR 1.1)

O group